Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Diabetes Care

• Publication date

  2014-12-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc14-0649PMID 25524950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily

  2013cited by this paper
• Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes

  2013cited by this paper
• Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

  2013cited by this paper
• Pharmacokinetics and pharmacodynamics of basal insulins.

  2011cited by this paper
• Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects

  2011cited by this paper
• Dose-Response Effects of Insulin Glargine in Type 2 Diabetes

  2010cited by this paper
• Molecular clocks, type 2 diabetes and cardiovascular disease

  2008cited by this paper
• Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study

  2008cited by this paper
• Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application

  2008cited by this paper
• Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes

  2007cited by this paper
• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes

  2006cited by this paper
• When the Clock stops ticking, metabolic syndrome explodes

  2006cited by this paper
• Optimal timing of injection of once‐daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal‐times

  2006cited by this paper
• Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?

  2006cited by this paper
• Nuclear receptor expression links the circadian clock to metabolism.

  2006cited by this paper
• Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride.

  2005cited by this paper
• Measurement of Insulin Absorption and Insulin Action

  2004influential reference
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin

  2004cited by this paper
• Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

  2003cited by this paper
• A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.

  2003cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes

  2003influential reference
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003cited by this paper
• Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution

  2002cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Physiology of glucose homeostasis

  2000cited by this paper
• Assessment of methods for improving tracer estimation of non-steady-state rate of appearance.

  1999cited by this paper
• Roles of circadian rhythmicity and sleep in human glucose regulation.

  1997cited by this paper
• Evidence for a Circadian Rhythm of Insulin Sensitivity in Patients With NIDDM Caused by Cyclic Changes in Hepatic Glucose Production

  1996influential reference
• Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis

  1993cited by this paper
• The "dawn phenomenon"--a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus.

  1984cited by this paper
• The Dawn Phenomenon, an Early Morning Glucose Rise: Implications for Diabetic Intraday Blood Glucose Variation

  1981cited by this paper
• Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics

  1977cited by this paper
• Manual feedback technique for the control of blood glucose concentration

  1966cited by this paper

• The Chronobiology of Hormone Administration: “Doctor, What Time Should I Take My Medication?”

  2025cites this paper
• Diabetes in Pregnancy and Major New Advances in Diabetes Care Using Long and Ultra-Long Acting Insulins.

  2025cites this paper
• Importance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes

  2025cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.

  2024cites this paper
• Commercially available injectables in diabetes – Insulin, incretins, and more

  2023cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.

  2023cites this paper
• Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage

  2023cites this paper
• Management of Type 2 Diabetes in Frail Older Adults

  2023cites this paper
• Timing Is Important—Management of Metabolic Syndrome According to the Circadian Rhythm

  2023cites this paper
• Assessment of circulating insulin using liquid chromatography‐mass spectrometry during insulin glargine treatment in type 2 diabetes: Implications for estimating insulin sensitivity and β‐cell function

  2023cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

  2022cites this paper
• Assessment of the Effect of Timing of Insulin Glargine Administration (bedtime versus morning) on Glycemic Control in Children with Type 1 Diabetes in Cairo, Egypt: A Single Centre Experience.

  2022cites this paper
• Factors Associated with Medicine Timing Effects: A Meta-analysis

  2021cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021.

  2020cites this paper
• Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline

  2020cites this paper
• Circadian Variation in Efficacy of Medications

  2020cites this paper
• Circadian Pharmacokinetics

  2020cites this paper
• Diabetes mellitus type 2 in adults

  2020cites this paper
• Basal insulin ameliorates post-breakfast hyperglycemia via suppression of post-breakfast proinsulin/C-peptide ratio and fasting serum free fatty acid levels in patients with type 2 diabetes

  2020cites this paper
• Role of Non-Pharmacokinetic Factors in Chronoefficacy

  2020cites this paper
• Engineered human FcγRIIa fusion: A novel strategy to extend serum half‐life of therapeutic proteins

  2020cites this paper
• Dietary Intake and Type 2 Diabetes

  2019cites this paper
• Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.

  2019cites this paper
• Insulin in Type 1 and Type 2 Diabetes—Should the Dose of Insulin Before a Meal be Based on Glycemia or Meal Content?

  2019cites this paper
• Glycosaminoglycan-Conjugated Insulin Derivatives Suitable for Once-Daily Formulations

  2019cites this paper
• Predictors of treatment response in type‐2 diabetes patients initiating basal‐supported oral therapy with insulin glargine 100 U/mL: A sub‐analysis of the Titration and OPtimisation (TOP) registry

  2019cites this paper
• Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers

  2019cites this paper
• Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use

  2019cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

  2019cites this paper
• Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial

  2018cites this paper
• [Improvement in the glycaemic control of patients after switching from human insulin to insulin glargine-based basal-bolus regimen].

  2018cites this paper
• Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies

  2018cites this paper
• Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019

  2018cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

  2018cites this paper
• Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

  2018cites this paper
• Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?

  2018cites this paper
• Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

  2017cites this paper
• The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial

  2017cites this paper
• Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH

  2017cites this paper
• Euglycaemic glucose clamp: what it can and cannot do, and how to do it

  2016cites this paper
• Glucodynamics of long‐acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial

  2016cites this paper
• Effects of Growth Hormone on Diurnal Insulin Sensitivity in Normal and Type 2 Diabetic Patients and Animal Models

  2016cites this paper
• Optimizing management of glycaemia.

  2016cites this paper
• The correlation of dawn phenomenon with glycemic variability parameters in type 2 diabetes mellitus

  2016cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2016cites this paper
• The Effects of Transition from Bedtime to Morning Glargine Administration in Patients with Poorly Regulated Type 1 Diabetes Mellitus: Croatian Pilot Study

  2015cites this paper
• New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice

  2015cites this paper
• How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

  2015cites this paper